These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36314703)

  • 41. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
    Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
    JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
    Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incapacitating solar urticaria: successful treatment with omalizumab.
    Kieselova K; Santiago F; Henrique M
    An Bras Dermatol; 2019 Jul; 94(3):331-333. PubMed ID: 31365663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
    J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
    Holm JG; Sørensen JA; Thomsen SF
    Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
    [No Abstract]   [Full Text] [Related]  

  • 47. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study.
    Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C
    J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611
    [No Abstract]   [Full Text] [Related]  

  • 49. Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data.
    Salman A; Aktas M; Apti Sengun O
    Australas J Dermatol; 2021 Aug; 62(3):398-402. PubMed ID: 34156714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.
    Asero R; Marzano AV; Ferrucci S; Genovese G; Cugno M
    Allergy; 2019 Dec; 74(12):2538. PubMed ID: 31165493
    [No Abstract]   [Full Text] [Related]  

  • 51. Refractory solar urticaria successfully treated with omalizumab with normalization of phototest.
    Combalia A; Fernández-Sartorio C; Aguilera P
    Actas Dermosifiliogr; 2017; 108(6):593-594. PubMed ID: 28168968
    [No Abstract]   [Full Text] [Related]  

  • 52. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
    Mehta H; Bishnoi A; Parsad D; Kumaran MS
    Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
    Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
    Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
    [No Abstract]   [Full Text] [Related]  

  • 55. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
    Farrah G; Stevenson B; Lie K; Brusch A
    Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
    Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
    [No Abstract]   [Full Text] [Related]  

  • 59. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.